The latest news......
ILD and ANCA
A large European multicentre study involving 162 patients provides important new insights into interstitial lung disease (ILD) associated with ANCA antibodies. The findings highlight that lung fibrosis is a serious and often under-recognised complication within the ANCA disease spectrum. One of the key messages emerging from this study is that patients with ANCA-associated ILD should ideally be managed by a multidisciplinary team. Although kidney involvement was common, it did not independently predict mortality. This suggests that lung disease severity at baseline may be the main driver of long-term outcomes in this population.
EMA starts Review Tavneos®
The current review is a so called Article 20 non-pharmacovigilance procedure. This type of procedure is used when questions arise about the scientific basis or robustness of the data that supported the original approval of a medicine.
It is not started because of new safety problems or concerns about side effects for patients.
Review Patient Summit 2025
In November, patients, caregivers, clinicians and researchers from more than a dozen European countries met in Prague for the 2025 European Vasculitis Patient Summit.
patients
Find Patient Advocacy Groups (VPAGs)
hospitals
Find vasculitis expertise
projects
Find out about the projects we are working on.